Results 91 to 100 of about 41,377 (182)

Nirmatrelvir-Ritonavir-Induced Pancreatitis: A Concern in the COVID Era. [PDF]

ACG Case Rep J
DeBroff J, Abraham J, Yoon BH, Cohen I.
europepmc   +1 more source

Still Treating Yesterday's Risk? Reconsidering Antiviral Use for Mild-to-Moderate COVID-19 Cases in a Broadly Immune Population. [PDF]

Med J Aust
Mudrik-Zohar H, Cutfield T, Morpeth S, Hills T, Duffy E, Edwards LJ, Cheng AC, Tong SYC.   +7 more
europepmc   +1 more source

Nirmatrelvir/Ritonavir Efficacy in Immunocompetent Patients with Confirmed Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2: An Updated Systematic Review and Meta-analysis. [PDF]

J Res Pharm Pract
Khani E, Afsharirad H, Yadegari AT, Zarezadeh M, Asham H, Bannazadeh-Baghi H, Entezari-Maleki T.   +6 more
europepmc   +1 more source

Pharmacokinetic drug-drug interaction between the COVID-19 3CL protease inhibitor GST-HG171 and itraconazole in healthy subjects. [PDF]

Antimicrob Agents Chemother
Li X, Li B, Wang M, Wang J, Lu J, Mao J, Zhang T, Tang Y, Yan W, Li C, Zhang G, Ding Y.   +11 more
europepmc   +1 more source

A Phase 1 Multiple-Dose, Open-Label, Pharmacokinetic Study of Nirmatrelvir/Ritonavir in Healthy Lactating Women. [PDF]

Clin Transl Sci
Gerhart J, Cheruvu N, Pelletier K, Matschke K, Shi H, Mfopou JK, Hammond J, Singh RSP.   +7 more
europepmc   +1 more source

Patient Characteristics and Healthcare Resource Use among Patients With COVID-19 Receiving Treatment with Nirmatrelvir/Ritonavir (PAXLOVID™) in the Kingdom of Saudi Arabia. [PDF]

Pulm Ther
Alraddadi BM, Almaghrabi RS, Bosaeed M, Kamal M, Hassanien A, Hammam H, Zanotti G, Ikizler BK, d'Hellencourt FL, Spinardi JR, Wang L, Kyaw MH.   +11 more
europepmc   +1 more source

Physiologically Based Pharmacokinetic Model to Predict Drug-Drug Interactions With the Antibody-Drug Conjugate Trastuzumab Deruxtecan. [PDF]

CPT Pharmacometrics Syst Pharmacol
Watanabe A, Gill KL, Chen KF, Jones HM, De Sousa Mendes M, Gardner I, Kotsuma M.   +6 more
europepmc   +1 more source

The Impact of the Core-Shell Fiber Composition on the Properties and Stability of the Electrospun Films

Nanotechnology, Science and Applications
Ewelina Łyszczarz,1 Aleksandra Rezka,1 Dorota Majda,2 Witold Jamróz,1 Aleksander Mendyk1 1Chair of Pharmaceutical Technology and Biopharmaceutics, Faculty of Pharmacy, Jagiellonian University Medical College, Cracow, Lesser Poland Voivodeship,
Łyszczarz E, Rezka A, Majda D, Jamróz W, Mendyk A   +4 more
doaj  

Repurposing anti-retroviral drugs to treat NF2-related tumours: a protocol for a phase 0 trial (RETREAT). [PDF]

BMJ Open
Campbell S, Beaney K, Hosking J, Sorrell L, Allgar V, Aspinall PJ, Ammoun S, Evans DG, Hanemann CO, Kingdon S.   +9 more
europepmc   +1 more source

A randomized controlled Phase I de-escalation trial of molnupiravir and nirmatrelvir/ritonavir combination for mild-moderate SARS-CoV-2 infection. [PDF]

J Antimicrob Chemother
Khoo SH, FitzGerald R, Edwards CJ, Ahmad S, Saunders G, Else LJ, Shaw V, Mozgunov P, Northey J, Dickinson L, Knox E, Buadi A, Hale C, Reynolds HE, Middleton C, Bullock K, Walker L, Walker L, Tetlow M, Lyon R, Gibney J, Amara A, Greenhalf W, Burdon A, Dixon J, Jaki T, Chiong J, Lalloo DG, Owen A, Jacobs M, Fletcher T, Griffiths G, AGILE CST-8 study group .   +32 more
europepmc   +1 more source